Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

The drug binds to VEGF – the same target as $8 billion blockbuster Eylea (aflibercept) – as well as a second target Ang-2, tackling two disease pathways associated with the sight-robbing diseases.